丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01513 丽珠医药

休市中 04-30 16:08:13

28.160

-0.100

-0.35%

最高28.440	最低27.980	成交量69.13万
今开28.280	昨收28.260	日振幅1.63%
总市值250.06亿	流通市值84.48亿	总股本8.88亿
成交额1,947万	换手率0.23%	流通股本3.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":28.16,"timestamp":1777536493003,"preClose":28.26,"halted":0,"volume":691300,"delay":0,"changeRate":-0.0035385704175513594,"floatShares":300000000,"shares":888000000,"eps":2.6038873480005016,"marketStatus":"休市中","change":-0.1,"latestTime":"04-30 16:08:13","open":28.28,"high":28.44,"low":27.98,"amount":19472202,"amplitude":0.016277,"askPrice":28.16,"askSize":5300,"bidPrice":28.1,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":2.52836429112605,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":7,"adr":0,"listingDate":1389801600000,"exchange":"SEHK","adjPreClose":28.26,"dividendRate":0.058301,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":0.7652124863149783,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":32.65,"timestamp":1777532400000,"preClose":32.83,"halted":0,"volume":5327000,"delay":0,"premium":"-24.81"}},"requestUrl":"/m/hq/s/01513","defaultTab":"news","newsList":[{"id":"1143836837","title":"丽珠医药最新进展：LIAN SGP完成对越南IMP要约收购，持股升至67.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143836837","media":"公告速递","labels":["shareholding","merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143836837?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:55","pubTimestamp":1777467357,"startTime":"0","endTime":"0","summary":"丽珠医药集团披露，其全资子公司 LIAN SGP HOLDING PTE.LTD. 已结束对越南上市企业 Imexpharm Corporation的公开要约收购。根据越南国家证券委员会相关规定，LIAN SGP 此次要约收购的价格为每股 57,400 越南盾，对应约人民币 15.37 元。要约期间结束后，LIAN SGP 实际收购 104,545,781 股，占 IMP 注册资本的 67.87%，相当于有表决权股份的 67.88%。截至公告日，丽珠医药董事会成员包括执行董事唐阳刚、非执行董事朱保国（董事长）等多人，信息披露符合监管要求。公司将继续跟进交易后续事宜并依法履行信息披露义务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630870132","title":"国产司美格鲁肽“首证”缓发？多家申报企业称专利悬崖过后还有数据保护期","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870132","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630870132?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:05","pubTimestamp":1777107938,"startTime":"0","endTime":"0","summary":"司美格鲁肽保护期的延长或将导致国产司美的“内卷”进一步加剧。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260425/20260425170827_99857.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260425/20260425170827_99857.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","01513","LU0154236417.USD","LU1093756168.USD","BK0028","LLY","BK0188","NVO","NVOX","IE00BZ1G4Q59.USD","BK4532","BK0187","BK0239","BK4007","02566","BK4599","BK4588","BK4585","LU1093756325.SGD","000513","IE00BKVL7J92.USD","NVOH"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1180743900","title":"丽珠医药将于2026年7月13日派发末期股息每股1.43元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180743900","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180743900?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:41","pubTimestamp":1776955319,"startTime":"0","endTime":"0","summary":"丽珠医药(01513)发布公告称，将于2026年7月13日向于2026年6月17日登记在册的股东派发2025年12月31日止年度末期股息。每10股派14.3元人民币，折合每股1.43元人民币。\n股东批准日期为2026年5月29日，除净日定于2026年6月16日，股权登记的最后时限为2026年6月17日16时30分。公告显示，本次股息派发所涉非中国内地登记地址非居民企业将分别预扣10%或20%的所得税。\n根据公告，董事会成员包括执行董事唐阳刚，非执行董事朱保国、林楠棋、邱庆丰，职工董事冉永梅及独立非执行董事白华、罗会远、崔丽婕、王智瑶。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠医药将于2026年7月13日派发末期股息每股1.43元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629853891","title":"丽珠医药(01513)将于7月13日派发末期股息每10股14.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629853891","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629853891?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:37","pubTimestamp":1776955066,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，将于2026年7月13日派发2025年12月31日止年度末期股息每10股14.3元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4588","BK4585","VIG","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629583061","title":"丽珠医药(01513)一季度归母净利润5.77亿元，同比下降9.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629583061","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629583061?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:48","pubTimestamp":1776952092,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药 发布公告，2026年第一季度，公司实现营业收入人民币28.71亿元，同比下降9.73%;归属于上市公司股东的净利润人民币5.77亿元，同比下降9.39%。受行业政策调整过渡期的影响和一季度流感、呼吸道感染发病率等季节波动性影响，公司营业收入同比有所波动，但公司整体经营表现稳健，核心业务的经营质量保持坚挺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104522755","title":"丽珠医药2026年第一季度营收28.71亿元，经调整净利润5.79亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104522755","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104522755?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:41","pubTimestamp":1776951690,"startTime":"0","endTime":"0","summary":"2026年第一季度，丽珠医药实现营业收入28.71亿元，同比下降9.73%。经调整净利润为5.79亿元，同比下降6.48%。经营活动产生的现金流量净额为8.17亿元，同比增长12.80%。从成本结构来看，本期销售费用为7.35亿元，同比下降约8.06%；管理费用为1.33亿元，同比下降约13.25%；研发费用为1.69亿元，同比下降约21.60%，占营业收入的约5.90%。公司表示，一季度营收波动主要受流感及呼吸道感染发病率回落、部分集采品种价格体系调整过渡、以及原料药板块订单季节性影响所致。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠医药2026年第一季度营收28.71亿元，经调整净利润5.79亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629839208","title":"丽珠医药(01513)提名刘大平、唐阳刚为执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2629839208","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629839208?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:12","pubTimestamp":1776946328,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，鉴于公司第十一届董事会任期将于2026年6月20日届满，经与会董事认真审议，一致同意提名朱保国先生、林楠棋先生及邱庆丰先生为公司第十二届董事会非执行董事候选人，提名刘大平先生、唐阳刚先生为公司第十二届董事会执行董事候选人。鉴于公司第十一届董事会任期将于2026年6月20日届满，经与会董事认真审议，一致同意提名罗会远先生、崔丽婕女士、康立女士、王智瑶女士为公司第十二届董事会独立董事候选人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627000107","title":"丽珠医药JP-1366根除幽门螺杆菌临床获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2627000107","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627000107?lang=zh_cn&edition=full","pubTime":"2026-04-13 09:14","pubTimestamp":1776042842,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月13日，丽珠医药官微宣布，公司研发的创新钾离子竞争性酸阻滞剂（P-CAB）JP-1366片用于根除幽门螺杆菌（Hp）的临床试验申请（IND）已获国家药品监督管理局（NMPA）正式批准。该药物的片剂用于反流性食管炎治疗已进入上市审评审批阶段，注射剂用于消化性溃疡出血治疗则处于Ⅱ期临床阶段。基于该药物现有研发基础，本次新增适应症获批后，可直接进入Ⅲ期临床试验阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702420395.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702420395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626219671","title":"丽珠医药(01513)：JP-1366片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626219671","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626219671?lang=zh_cn&edition=full","pubTime":"2026-04-10 18:05","pubTimestamp":1775815509,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，近日，丽珠医药集团股份有限公司 Livzon Pharmaceutical Group Inc.*收到国家药品监督管理局核准签发的《药物临床试验批准通知书》(通知书编号：2026LP01115)，同意公司申报的申报的 JP-1366 片开展“与适当的抗生素联用以根除幽门螺杆菌”适应症的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179745077","title":"港股创新药概念股盘初走高！丽珠医药涨超4%，歌礼制药涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179745077","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179745077?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:37","pubTimestamp":1775698645,"startTime":"0","endTime":"0","summary":"创新药概念股盘初走高，$丽珠医药(01513)$涨超4%，$歌礼制药-B(01672)$、$康诺亚-B(02162)$涨超3%，$翰森制药(03692)$、$信达$、生物(01801)$、$药明康德(02359)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c276b56633daca2a66332a5543287c45","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","01513","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518996","title":"丽珠医药(01513.HK)拟4月10日举办2025年年度报告业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518996","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624518996?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:37","pubTimestamp":1775043422,"startTime":"0","endTime":"0","summary":"格隆汇4月1日丨丽珠医药(01513.HK)公告，为了加强与公司投资者，特别是中小投资者的沟通和交流，进一步了解公司经营业绩及未来发展情况，公司将于2026年4月10日(星期五)15:00至17:00在全景网举办公司2025年年度报告业绩说明会，本次业绩说明会将采用网络远程的方式举行，投资者可登录全景网“投资者关系互动平台”(http://ir.p5w.net)参与本次业绩说明会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260401/32119243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164443248","title":"丽珠医药3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1164443248","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164443248?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:26","pubTimestamp":1775035607,"startTime":"0","endTime":"0","summary":"丽珠医药集团股份有限公司（股票代码：01513）于2026年4月1日发布截至2026年3月31日的股份变动月报表，报告期内公司股本结构保持稳定，未有新增发行、购回或注销记录。\n公告显示，截至3月末，公司注册股本总额为人民币887,907,171元。其中，H股数量为299,807,117股，A股数量为588,100,054股，均与上月底持平。此外，报告期内未发生任何期权、股权激励及可换股债券等变动事项。\n综合本次月报情况，公司股本规模维持不变。公司同时确认遵守香港联交所《上市规则》及相关法律监管要求。公告由公司秘书刘宁签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192824611","title":"丽珠医药(01513)将于股东大会审议后派发2025年度股息每股1.43元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192824611","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192824611?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:06","pubTimestamp":1774526783,"startTime":"0","endTime":"0","summary":"丽珠医药(01513)公告显示，公司就截至2025年12月31日止年度的利润分配预案进行补充说明，拟以股权登记日的公司总股本为基数，每10股派发现金股利人民币14.30元（含税），即折合每股1.43元（含税），不送红股，也不以资本公积金转增股本。\n本次派息计划尚需提交公司2025年度股东大会审议批准。若获通过，公司将依照股权登记日确定的持股数量，向全体股东派付相应金额，具体派付日期及安排将另行公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851296","title":"丽珠医药(01513)：注射用布瑞哌唑微球获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851296","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622851296?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:13","pubTimestamp":1774523600,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药 发布公告，近日，公司全资控股子公司珠海市丽珠微球科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司申报的注射用布瑞哌唑微球开展用于成人精神分裂症的临床试验。注射用布瑞哌唑微球为公司自主研发的缓释微球制剂，是新一代精神分裂症的治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠医药(01513)：注射用布瑞哌唑微球获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133668522","title":"丽珠医药将于派息日有待公布派发末期股息每股1.43元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133668522","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133668522?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:22","pubTimestamp":1774358520,"startTime":"0","endTime":"0","summary":"丽珠医药(01513)\n根据公司公告，丽珠医药集团股份有限公司2025年12月31日止年度拟派发末期股息，每10股派发14.3元人民币，折合每股1.43元人民币，最终派息金额以公司公布为准。\n本次股息派发仍须待股东批准，具体除净日、过户登记截止日期及派息日期尚未确定，相关信息将另行公告。公司拟派息货币为港币，实际金额及汇率亦有待公布。\n公司董事会成员包括执行董事唐阳刚先生，非执行董事朱保国先生、林楠棋先生及邱庆丰先生，职工董事冉永梅女士，以及独立非执行董事白华先生、罗会远先生、崔丽婕女士、王智瑶女士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621060689","title":"丽珠医药(01513)将派发末期股息每10股14.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621060689","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621060689?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:18","pubTimestamp":1774358282,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，将派发截至2025年12月31日止年度末期股息每10股14.3元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VIG","01513","BK4588","BK4585","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067093","title":"丽珠医药(01513)：冉永梅获委任为董事会战略委员会委员","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067093","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621067093?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:07","pubTimestamp":1774357658,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，于2026年3月24日，公司职工代表董事冉永梅女士已获委任为董事会战略委员会委员，执行董事唐阳刚先生已获委任为董事会提名委员会委员，自2026年3月24日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134372153","title":"丽珠医药(01513)：收入稳步增长，核心业务板块分化明显，治理与风险管理持续完善","url":"https://stock-news.laohu8.com/highlight/detail?id=1134372153","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134372153?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:06","pubTimestamp":1774357563,"startTime":"0","endTime":"0","summary":"丽珠医药在报告期内的合并口径营业收入由人民币118.1234亿元上升至人民币120.2035亿元，同比增长1.76%。归属于公司股东的净利润为人民币20.2323亿元，同比下降1.84%；扣除非经常性损益后归属于公司股东的净利润为人民币20.0916亿元，同比上升1.51%。期内利润总额为人民币28.6205亿元，同比增长1.99%。经营活动产生的现金流量净额为人民币31.4504亿元，同比增长5.58%。综上所述，丽珠医药在本期实现了营业收入的总体稳步增长，净利润略有下滑但扣非后保持正向增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062665","title":"丽珠医药(01513)拟使用不超过25亿元的闲置自有资金购买委托理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062665","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621062665?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:29","pubTimestamp":1774355395,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)公布，公司及子公司拟使用不超过人民币25亿元(含)的闲置自有资金购买委托理财产品。在授权额度范围内，资金可滚动使用，任一时点使用闲置自有资金购买理财产品的投资总额(含前述投资的收益进行再投资的相关金额)不超过上述投资额度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618750138","title":"业绩乏力，丽珠医药高管大换血","url":"https://stock-news.laohu8.com/highlight/detail?id=2618750138","media":"蓝鲸财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618750138?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:14","pubTimestamp":1773310451,"startTime":"0","endTime":"0","summary":"不过，近年来，这家老牌制药企业出现业绩乏力，而高管团队的“新老交替”能否为这家企业带来新的生机引发业内关注。公开信息显示，丽珠医药业务高度聚焦制药，横跨化药、原料药、中药、生物药及诊断试剂五大领域。除了化学板块，丽珠医药2025年半年报显示，其原料药与中间体板块因头孢类产品受国内市场价格波动影响，整体收入同比下降5.65%；诊断试剂及设备板块也因呼吸道产品周期变化，在去年同期高基数基础上，收入同比下滑5.13%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773309216313250615","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.livzon.com.cn","stockEarnings":[{"period":"1week","weight":0.0036},{"period":"1month","weight":0.027},{"period":"3month","weight":-0.0422},{"period":"6month","weight":-0.0992},{"period":"1year","weight":0.1329},{"period":"ytd","weight":-0.0126}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"丽珠医药集团股份有限公司是一家主要从事医药产品的研发、生产及销售业务的中国公司。该公司的主要业务包括化学制剂、生物制品、原料药及中间体、中药制剂、诊断试剂和设备，以及商业发展和职能管理。该公司的主要产品品牌包括“壹丽安”（艾普拉唑肠溶片及注射用艾普拉唑钠）、“丽珠得乐”（枸橼酸铋钾）系列产品、“丽倍乐”（雷贝拉唑钠肠溶胶囊）、“维三联”（枸橼酸铋钾片/替硝唑片/克拉霉素片）、“贝依”（注射用醋酸亮丙瑞林微球）、“丽申宝”（注射用尿促卵泡素）、“乐宝得”（注射用尿促性素）、“丽福康”（注射用伏立康唑）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.001134},{"month":2,"riseRate":0.538462,"avgChangeRate":0.025407},{"month":3,"riseRate":0.538462,"avgChangeRate":0.022432},{"month":4,"riseRate":0.692308,"avgChangeRate":0.031864},{"month":5,"riseRate":0.416667,"avgChangeRate":0.013787},{"month":6,"riseRate":0.5,"avgChangeRate":0.000101},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.018444},{"month":8,"riseRate":0.5,"avgChangeRate":0.000715},{"month":9,"riseRate":0.454545,"avgChangeRate":0.011936},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.019823},{"month":11,"riseRate":0.583333,"avgChangeRate":0.03425},{"month":12,"riseRate":0.5,"avgChangeRate":-0.008149}],"exchange":"SEHK","name":"丽珠医药","nameEN":"LIVZON PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠医药(01513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠医药,01513,丽珠医药股票,丽珠医药股票老虎,丽珠医药股票老虎国际,丽珠医药行情,丽珠医药股票行情,丽珠医药股价,丽珠医药股市,丽珠医药股票价格,丽珠医药股票交易,丽珠医药股票购买,丽珠医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠医药(01513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}